 Connection
Elizabeth Kessler to Prostatic Neoplasms, Castration-Resistant
This is a "connection" page, showing publications Elizabeth Kessler has written about Prostatic Neoplasms, Castration-Resistant.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.731 |
|
|
|
-
Kessler ER, Flaig TW. Sequencing medical therapy in prostate cancer: not as easy as 1-2-3. Oncology (Williston Park). 2013 Nov; 27(11):1158-60.
Score: 0.380
-
Choudhury AD, Zhong C, Xie W, Kochupurakkal BS, Wu PI, Riaz IB, Liu R, Yang DD, Folefac E, Lee D, Parikh M, Einstein DJ, Kessler ER, Mayer T, McKay RR, Pace A, Mouw KW, Chen L, Adalsteinsson VA, Van Allen EM, Kunos CA, Gore SD, Das B, D'Andrea A, Taplin ME, Shapiro GI. A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer. Cancer Res Commun. 2026 Sep 01; 6(9):2206-2219.
Score: 0.231
-
Kessler ER, Gao D, Flaig TW, Breaker K, Wold M, Wacker M, Lam ET. Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. Ann Oncol. 2017 03 01; 28(3):668.
Score: 0.120
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|